No connection

Search Results

BRKR vs KRYS

BRKR
Bruker Corporation
BEARISH
Price
$50.33
Market Cap
$7.65B
Sector
Healthcare
AI Confidence
75%
KRYS
Krystal Biotech, Inc.
NEUTRAL
Price
$259.00
Market Cap
$7.62B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
BRKR
--
KRYS
37.87
Forward P/E
BRKR
23.49
KRYS
24.48
P/B Ratio
BRKR
3.13
KRYS
6.2
P/S Ratio
BRKR
2.22
KRYS
19.59
EV/EBITDA
BRKR
16.18
KRYS
41.45

Profitability

Gross Margin
BRKR
48.83%
KRYS
94.08%
Operating Margin
BRKR
12.96%
KRYS
41.33%
Profit Margin
BRKR
-0.61%
KRYS
52.64%
ROE
BRKR
-1.09%
KRYS
18.91%
ROA
BRKR
3.69%
KRYS
8.44%

Growth

Revenue Growth
BRKR
-0.5%
KRYS
17.5%
Earnings Growth
BRKR
--
KRYS
11.6%

Financial Health

Debt/Equity
BRKR
0.82
KRYS
0.01
Current Ratio
BRKR
1.85
KRYS
9.95
Quick Ratio
BRKR
0.84
KRYS
9.28

Dividends

Dividend Yield
BRKR
0.38%
KRYS
--
Payout Ratio
BRKR
38.46%
KRYS
0.0%

AI Verdict

BRKR BEARISH

The Advanced Deterministic Scorecard reveals a weak fundamental profile with a Piotroski F-Score of just 2/9, indicating poor financial health. Despite a reasonable Price/Book of 3.13 and a Forward P/E of 23.49 that is below sector average, the company is unprofitable with a negative profit margin (-0.61%) and ROE (-1.09%). Revenue is flat, earnings volatility is high, and insider selling of $2.76M over the past six months signals management skepticism. While the technical rebound from 6-month lows has lifted price performance (+20.3% over 6M), the long-term trend remains weak with a 3Y return of -28.5%, and analyst target of $54.07 appears optimistic given deteriorating fundamentals.

Strengths
Gross margin remains strong at 48.83%, indicating pricing power or efficient cost control at production level
Operating margin of 12.96% is healthy relative to sector average of -18.86%
Current ratio of 1.85 suggests adequate short-term liquidity
Risks
Piotroski F-Score of 2/9 signals severe financial distress and weak earnings quality
Negative net profit margin (-0.61%) and ROE (-1.09%) indicate core profitability issues
Revenue growth is negative YoY (-0.50%), reflecting stagnation in top line
KRYS NEUTRAL

KRYS presents a dichotomy between exceptional operational efficiency and poor valuation metrics. The company exhibits a weak Piotroski F-Score (3/9), suggesting deteriorating financial trends despite a pristine balance sheet with nearly zero debt and a high current ratio (9.95). While gross margins are elite at 94.08%, the stock trades at a significant premium to its Graham Number ($80.18) and Intrinsic Value ($166.9). Heavy insider selling and a bearish technical trend offset the 'Strong Buy' analyst consensus, suggesting the current price reflects peak optimism.

Strengths
Exceptional gross margins of 94.08% indicating strong pricing power
Virtually debt-free balance sheet with a Debt/Equity ratio of 0.01
Extreme liquidity with a Current Ratio of 9.95
Risks
Significant overvaluation relative to intrinsic value ($259 vs $166.9)
Aggressive insider liquidation totaling $63.13M in the last 6 months
Low Piotroski F-Score (3/9) indicating weak fundamental momentum

Compare Another Pair

BRKR vs KRYS: Head-to-Head Comparison

This page compares Bruker Corporation (BRKR) and Krystal Biotech, Inc. (KRYS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile